Search for 'Provider:Pharmacogenetics and Genomics,'

Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.

By Joven Ibáñez, Beatriz Esther | Carreira Delgado, Patricia Esmeralda. Pharmacogenetics and genomics, 2014 . 24(5):238-45. , Formato Vancouver: Montes A, Pérez-Pampin E, Narváez J, Cañete JD, Navarro-Sarabia F, Moreira V et al. Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis. Pharmacogenet Genomics. 2014 May;24(5):238-45.

Place Hold on Association of FCGR2A with the response to infliximab treatment of patients with rheumatoid arthritis.

PharmGKB summary: methylene blue pathway

By Bautista, José M.. Pharmacogenetics and genomics, 2013 . 23(9):498-508. , Formato Vancouver: McDonagh EM, Bautista JM, Youngster I, Altman RB, Klein TE. PharmGKB summary: methylene blue pathway. Pharmacogenet Genomics. 2013 Sep;23(9):498-508.

Place Hold on PharmGKB summary: methylene blue pathway

No association of the SLC1A2 rs3794087 allele with risk for essential tremor in the Spanish population.

By Benito León, Julián. Pharmacogenetics and Genomics, 2013 . 23(11):587-90. , Formato Vanocuver: García-Martín E, Martínez C, Alonso-Navarro H, Benito-León J, Lorenzo-Betancor O, Pastor P et al. No association of the SLC1A2 rs3794087 allele with risk for essential tremor in the Spanish population. Pharmacogenet Genomics. 2013 Nov;23(11):587-90.

Place Hold on No association of the SLC1A2 rs3794087 allele with risk for essential tremor in the Spanish population.

PharmGKB summary: very important pharmacogene information for G6PD.

By Bautista, José M.. Pharmacogenetics and Genomics, 2012 . 22(3):219-28. , Formato Vancouver: McDonagh EM, Thorn CF, Bautista JM, Youngster I, Altman RB, Klein TE. PharmGKB summary: very important pharmacogene information for G6PD. Pharmacogenet Genomics. 2012 Mar;22(3):219-28.

Place Hold on PharmGKB summary: very important pharmacogene information for G6PD.